Takeda is rumored to be in discussions with Nycomed to purchase the latter company for between $12 and $14 billion. The former is said to be lining up financing with several banks and has hired Deutsche Securities as an advisor on the deal.
A purchase of this magnitude would be the second biggest takeover ever by a Japanese firm. In acquiring Nycomed, Takeda would pick up the former's to selling drug pantoprazole for heartburn (complementing its own Prevacid), the lung drug roflumilast, sold as Daxas in Europe and Daliresp in the US, for the treatment of COPD.
The purchase would also give Takeda a presence in Europe and in emerging markets which have been a focus of Nycomed's growth. Emerging markets accounted for 39 percent of Nycomed's 3.2 billion in 2010 revenue with sales in Latin America up 29.8% and in Russia up 23.3%. Nycomed also bought a majority stock position in a Chinese pharma company, Guandong Techpool Bio-Pharma, last year. Takeda would also pick up Nycomed R&D operations in India.
This purchase would seem similar in strategic intent to Takeda's nearly $9 billion purchase of Millenium Pharmaceuticals in 2008. It will increase the strength of Takeda's pipeline in some targeted therapeutic areas: osteoporosis, gastroenterology, and respiratory diseases.
Posted by Bruce Lehr May 12th 2011.